细胞治疗技术研发商BioAtla宣布BA3361治疗多种肿瘤的IND申请获FDA批准-动脉橙

细胞治疗技术研发商BioAtla宣布BA3361治疗多种肿瘤的IND申请获FDA批准

2024-05-06 RTTNews 等3家媒体报道 FDA动态





BioAtla，Inc.宣布，FDA已批准其IND应用程序，以评估BA3361，一种用于治疗多种肿瘤的CAB-Nectin-4 ADC。BA3361是第一个具有BioAtla改进的NextGen ADC接头的分子，靶向在恶性肿瘤中过表达的Nectin-4。它在胰腺癌模型中显示出优异的活性。（摘要由动脉网AI生成）

关联公司

 BioAtla

2024-05-06 BioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of Multiple Tumors

RTTNews
2024-05-06 BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioSpace
2024-05-07 BioAtla Receives FDA Clearance for Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate Targeting Multiple Tumors

PHARMA FOCUS ASIA